<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459868</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>COVID-19 in Relation to Polypharmacy and Immunization (2020-2024).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1533</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101533</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Observational studies reported worse COVID-19 evolution in relation to polypharmacy and reductions in COVID-19 hospital admissions and death in patients receiving chronic antihistamine treatment. The current profile of hospitalized patients with regard to different variants was analyzed to identify specific targets for future prospective trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">COVID-19 admissions to the Hospital of Terrassa (11 March 2020-28 August 2024 (n = 1457), from the integral Consorci Sanitari de Terrassa population (n = 167,386 people) were studied. Age, gender, the number of chronic treatments (nT), and immunization status were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After 5 May 2023, 291 patients (54% females) required COVID hospitalization. Of these, 39% received &gt;8 nT (23% receiving 5-7 nT), 70.2% were &gt;70 years, and 93.4% survived. In total, 12% of patients admitted after 5 May 2024 were not vaccinated, while 59% received ≥4 vaccines (43% within the last 12 months). In total, 49% of admitted patients presented no previous infection (while 3% presented infection during the last year). Delta or Omicron variants would have accounted for ≥80% of admissions &gt; 60 years compared to the first pandemic wave if no vaccines existed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients &gt; 70 years who receive ≥5 nT, without prior COVID-19 infections, should be the priority for prevention, with updated vaccination and early treatments to reduce hospitalizations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puigdellívol-Sánchez</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7239-2953</Identifier><AffiliationInfo><Affiliation>Medicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Surgical Neuroanatomy, Human Anatomy and Embryology Unit, Faculty of Medicine, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juanes-González</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8682-6000</Identifier><AffiliationInfo><Affiliation>Medicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calderón-Valdiviezo</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valls-Foix</LastName><ForeName>Roger</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1016-4039</Identifier><AffiliationInfo><Affiliation>Medicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-Salvador</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Management, Control and Information Analysis Unit, Hospital Universitari de Terrassa, Consorci Sanitari de Terrassa, Carretera de Torrebonica s/n, 08227 Terrassa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozano-Paz</LastName><ForeName>Celia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2301-2509</Identifier><AffiliationInfo><Affiliation>Medicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal-Alaball</LastName><ForeName>Josep</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3527-4242</Identifier><AffiliationInfo><Affiliation>Intelligence for Primary Care Research Group, Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina, c/ Soler i March 6, 08242 Manresa, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unitat de Recerca i Innovació, Gerència d'Atenció Primària i a la Comunitat de la Catalunya Central, Institut Català de la Salut, c/ Soler i March 6, 08242 Manresa, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019338" MajorTopicYN="Y">Polypharmacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">death rate</Keyword><Keyword MajorTopicYN="N">hospital admission</Keyword><Keyword MajorTopicYN="N">polypharmacy</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459868</ArticleId><ArticleId IdType="pmc">PMC11512247</ArticleId><ArticleId IdType="doi">10.3390/v16101533</ArticleId><ArticleId IdType="pii">v16101533</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>University of Oxford-Oxford Martin School  Official Data Collated by Our World in Data—Last Updated August 7th 2024—Processed by Our World in Data.  [(accessed on 4 July 2024)].  Available online:  https://ourworldindata.org/grapher/current-covid-hospitalizations-per-million.</Citation></Reference><Reference><Citation>Fadel R., Morrison A.R., Vahia A., Smith A.R., Chaudhry Z., Bhargava P., Miller J., Kenney R.M., Alangaden G., Ramesh M.S. Early Short-Course Corticosteroids in Hospitalized Patients with COVID-19. Clin. Infect. Dis. 2020;71:2114–2120. doi: 10.1093/cid/ciaa601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa601</ArticleId><ArticleId IdType="pmc">PMC7314133</ArticleId><ArticleId IdType="pubmed">32427279</ArticleId></ArticleIdList></Reference><Reference><Citation>Terpos E., Ntanasis-Stathopoulos I., Elalamy I., Kastritis E., Sergentanis T.N., Politou M., Psaltopoulou T., Gerotziafas G., Dimopoulos M.A. Hematological findings and complications of COVID-19. Am. J. Hematol. 2020;95:834–847. doi: 10.1002/ajh.25829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25829</ArticleId><ArticleId IdType="pmc">PMC7262337</ArticleId><ArticleId IdType="pubmed">32282949</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Fountaine R.J., Yunis C., Fleishaker D., Almas M., Bao W., Wisemandle W., Baniecki M.L., Hendrick V.M., Kalfov V., et al. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with COVID-19. N. Engl. J. Med. 2024;390:1186–1195. doi: 10.1056/NEJMoa2309003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2309003</ArticleId><ArticleId IdType="pmc">PMC11156287</ArticleId><ArticleId IdType="pubmed">38598573</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghioff S.M., Slavin B.R., Holton T., Singh D. Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 75754 patients. PLoS ONE. 2021;16:e0255541. doi: 10.1371/journal.pone.0255541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255541</ArticleId><ArticleId IdType="pmc">PMC8330918</ArticleId><ArticleId IdType="pubmed">34343191</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragni P., Marino M., Formisano D., Bisaccia E., Scaltriti S., Bedeschi E., Grilli R. Association between exposure to influenza vaccination and COVID-19 diagnosis and outcomes. Vaccines. 2020;8:675. doi: 10.3390/vaccines8040675.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8040675</ArticleId><ArticleId IdType="pmc">PMC7711765</ArticleId><ArticleId IdType="pubmed">33198368</ArticleId></ArticleIdList></Reference><Reference><Citation>Juanes-González M., Calderón-Valdiviezo A., Losa-Puig H., Valls-Foix R., González-Salvador M., León-Pérez M., Pueyo-Antón L., Lozano-Paz C., Franco-Romero M., Vidal-Alaball J., et al. COVID-19 first and delta waves in relation to ACEI, ARB, Influenza vaccination, and comorbidity in a North Metropolitan Barcelona Health Consortium. medRxiv. 2021 doi: 10.1101/2021.11.17.21265440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21265440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta N., Kalra A., Nowacki A.S., Anjewierden S., Han Z., Bhat P., Carmona-Rubio A.E., Jacob M., Procop G.W., Harrington S., et al. Association of Use of Angiotensin-Converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1020–1026. doi: 10.1001/jamacardio.2020.1855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1855</ArticleId><ArticleId IdType="pmc">PMC7201375</ArticleId><ArticleId IdType="pubmed">32936273</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen R.K., Conroy S.P., Taub N., Jones W., Bryden D., Pareek M., Faull C., Abrams K.R., Davis D., Banerjee J. Comparing associations between frailty and mortality in hospitalised older adults with or without COVID-19 infection: A retrospective observational study using electronic health records. Age Ageing. 2020;50:307–316. doi: 10.1093/ageing/afaa167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afaa167</ArticleId><ArticleId IdType="pmc">PMC7454252</ArticleId><ArticleId IdType="pubmed">32678866</ArticleId></ArticleIdList></Reference><Reference><Citation>Aryal K., Mowbray F.I., Miroshnychenko A., Strum R.P., Dash D., Hillmer M.P., Malikov K., Costa A.P., Jones A. Evaluating methods for risk prediction of COVID-19 mortality in nursing home residents before and after vaccine availability: A retrospective cohort study. BMC Med. Res. Methodol. 2024;24:77. doi: 10.1186/s12874-024-02189-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-024-02189-3</ArticleId><ArticleId IdType="pmc">PMC10976701</ArticleId><ArticleId IdType="pubmed">38539074</ArticleId></ArticleIdList></Reference><Reference><Citation>Morán-Blanco J.I., Alvarenga-Bonilla J.A., Homma S., Suzuki K., Fremont-Smith P., Villar-Gómez de Las Heras K. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care—A retrospective observational study in elderly patients. Pulm. Pharmacol. Ther. 2021;67:101989. doi: 10.1016/j.pupt.2021.101989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2021.101989</ArticleId><ArticleId IdType="pmc">PMC7833340</ArticleId><ArticleId IdType="pubmed">33465426</ArticleId></ArticleIdList></Reference><Reference><Citation>Morán-Blanco J.I., Alvarenga-Bonilla J.A., Fremont-Smith P., Villar-Gómez de Las Heras K. Antihistamines as an early treatment for COVID-19. Heliyon. 2023;9:e15772. doi: 10.1016/j.heliyon.2023.e15772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e15772</ArticleId><ArticleId IdType="pmc">PMC10129342</ArticleId><ArticleId IdType="pubmed">37128299</ArticleId></ArticleIdList></Reference><Reference><Citation>Puigdellívol-Sánchez A., Juanes-González M., Calderón-Valdiviezo A., Losa-Puig H., Valls-Foix R., González-Salvador M., Lozano-Paz C., Vidal-Alaball J. COVID-19 in Relation to Chronic Antihistamine Prescription. In Review in Pharmacological Reports.  [(accessed on 30 August 2024)].  Available online:  https://www.researchsquare.com/article/rs-4686775/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-4686775/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>CoVariants. Hodcroft E. Institute of Social and Preventive Medicine University of Bern, Switzerland &amp; SIB Swiss Insitute of Bioinformatics.  [(accessed on 30 August 2024)].  Available online:  https://covariants.org/</Citation></Reference><Reference><Citation>López M.G., Chiner-Oms Á., García de Viedma D., Ruiz-Rodriguez P., Bracho M.A., Cancino-Muñoz I., D’Auria G., de Marco G., García-González N., Goig G.A., et al. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. Nat. Genet. 2021;53:1405–1414. doi: 10.1038/s41588-021-00936-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00936-6</ArticleId><ArticleId IdType="pmc">PMC8481935</ArticleId><ArticleId IdType="pubmed">34594042</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez-Carballa A., Bello X., Pardo-Seco J., Pérez del Molino M.L., Martiñón-Torres F., Salas A. Phylogeography of SARS-CoV-2 pandemic in Spain: A story of multiple introductions, micro-geographic stratification, founder effects, and super-spreaders. Zool. Res. 2020;41:1–16. doi: 10.24272/j.issn.2095-8137.2020.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.24272/j.issn.2095-8137.2020.217</ArticleId><ArticleId IdType="pmc">PMC7671907</ArticleId><ArticleId IdType="pubmed">32935498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodcroft E.B., Zuber M., Nadeau S., Vaughan T.G., Crawford K.H., Althaus C.L., Reichmuth M.L., Bowen J.E., Walls A.C., Corti D., et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature. 2021;595:707–712. doi: 10.1038/s41586-021-03677-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03677-y</ArticleId><ArticleId IdType="pubmed">34098568</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean A.G., Sullivan K.M., Soe M.M. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Versión. Actualized 6 March 2013.  [(accessed on 1 June 2024)].  Available online:  www.openepi.com.</Citation></Reference><Reference><Citation>Vacunas y Programa de Vacunación  Datos de Vacunación COVID-19 en España. Ministerio de Sanidad.  [(accessed on 30 August 2024)].  Available online:  https://www.sanidad.gob.es/areas/alertasEmergenciasSanitarias/alertasActuales/nCov/documentos/Informe_GIV_Comunicacion_12042024.pdf.</Citation></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Gonzalo-Pérez M., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden R.L., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Costa-Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Corchado-Garcia J., Zemmour D., Hughes T., Bandi H., Cristea-Platon T., Lenehan P., Pawlowski C., Bade S., O’Horo J.C., Gores G.J., et al. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. JAMA Netw. Open. 2021;4:e2132540. doi: 10.1001/jamanetworkopen.2021.32540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.32540</ArticleId><ArticleId IdType="pmc">PMC8564583</ArticleId><ArticleId IdType="pubmed">34726743</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization.  [(accessed on 18 September 2024)].  Available online:  https://iris.who.int/bitstream/handle/10665/360580/WHO-2019-nCoV-SurveillanceGuidance-2022.2-eng.pdf.</Citation></Reference><Reference><Citation>Kucirka L.M., Lauer S.A., Laeyendecker O., Boon D., Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann. Intern. Med. 2020;173:262–267. doi: 10.7326/M20-1495.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-1495</ArticleId><ArticleId IdType="pmc">PMC7240870</ArticleId><ArticleId IdType="pubmed">32422057</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen M., Møller F.T., Gunalan V., Baig S., Bennedbæk M., Christiansen L.E., Cohen A.S., Ellegaard K., Fomsgaard A., Franck K.T., et al. First cases of SARS-CoV-2 BA.2.86 in Denmark, 2023. Eurosurveillance. 2023;28:2300460. doi: 10.2807/1560-7917.ES.2023.28.36.2300460.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.36.2300460</ArticleId><ArticleId IdType="pmc">PMC10486197</ArticleId><ArticleId IdType="pubmed">37676147</ArticleId></ArticleIdList></Reference><Reference><Citation>Nextrain.org  Genomic Epidemiology of SARS-CoV-2 with Subsampling Focused Globally over the Past 6 Months.  [(accessed on 29 August 2024)].  Available online:  https://nextstrain.org/ncov/gisaid/global/6m.</Citation></Reference><Reference><Citation>Hadfield J., Megill C., Bell S.M., Huddleston J., Potter B., Callender C., Sagulenko P., Bedford T., Neher R.A. Nextstrain: Real-time tracking of pathogen evolution. Bioinformatics. 2018;34:4121–4123. doi: 10.1093/bioinformatics/bty407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty407</ArticleId><ArticleId IdType="pmc">PMC6247931</ArticleId><ArticleId IdType="pubmed">29790939</ArticleId></ArticleIdList></Reference><Reference><Citation>Faksova K., Walsh D., Jiang Y., Griffin J., Phillips A., Gentile A., Kwong J.C., Macartney K., Naus M., Grange Z., et al. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024;42:2200–2211. doi: 10.1016/j.vaccine.2024.01.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.01.100</ArticleId><ArticleId IdType="pubmed">38350768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nextrain.org  Tree of SARS-CoV-2 Clades.  [(accessed on 29 August 2024)].  Available online:  https://github.com/nextstrain/ncov-clades-schema.</Citation></Reference><Reference><Citation>Takefuji Y. Exploring the connection between frailty and cardiovascular diseases. Arch. Gerontol. Geriatr. 2024;124:105449. doi: 10.1016/j.archger.2024.105449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2024.105449</ArticleId><ArticleId IdType="pubmed">38669728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M., Cano N., Segura B., Adan A., Bargalló N., Caldú X., Campabadal A., Jurado M.A., Mataró M., Pueyo R., et al. Neuropsychological impairment in post-COVID condition individuals with and without cognitive complaents. Front. Aging Neurosci. 2022;14:1029842. doi: 10.3389/fnagi.2022.1029842.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.1029842</ArticleId><ArticleId IdType="pmc">PMC9631485</ArticleId><ArticleId IdType="pubmed">36337708</ArticleId></ArticleIdList></Reference><Reference><Citation>Man M.A., Rosca D., Bratosin F., Fira-Mladinescu O., Ilie A.C., Burtic S.R., Fildan A.P., Fizedean C.M., Jianu A.M., Negrean R.A., et al. Impact of Pre-Infection COVID-19 Vaccination on the Incidence and Severity of Post-COVID Syndrome: A Systematic Review and Meta-Analysis. Vaccines. 2024;12:189. doi: 10.3390/vaccines12020189.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12020189</ArticleId><ArticleId IdType="pmc">PMC10893048</ArticleId><ArticleId IdType="pubmed">38400172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Kuang T., Liu X. Advances in researches on long coronavirus disease in children: A narrative review. Transl. Pediatr. 2024;13:318–328. doi: 10.21037/tp-23-472.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tp-23-472</ArticleId><ArticleId IdType="pmc">PMC10915432</ArticleId><ArticleId IdType="pubmed">38455739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortés-Borra A., Aranda-Abreu G.E. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol. Rep. 2021;73:962–965. doi: 10.1007/s43440-021-00231-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00231-5</ArticleId><ArticleId IdType="pmc">PMC7891470</ArticleId><ArticleId IdType="pubmed">33604795</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallahi M.J., Pezeshkian F., Ranjbar K., Javaheri R., Shahriarirad R. Evaluation of the predictors and frequency of silent hypoxemia in COVID-19 patients and the gap between pulse oximeter and arterial blood gas levels: A cross-sectional study. Health Care Sci. 2024;3:172–180. doi: 10.1002/hcs2.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hcs2.98</ArticleId><ArticleId IdType="pmc">PMC11212329</ArticleId><ArticleId IdType="pubmed">38947362</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaneri M., Matone M., Fassio F., Lai A., Bergna A., Della Ventura C., Galli L., Scaglione G., Gori A., Schiavini M. Exploring early COVID-19 therapies, variants, and viral clearance dynamics: Insights from a high-risk outpatients study. Diagn. Microbiol. Infect. Dis. 2024;110:116452. doi: 10.1016/j.diagmicrobio.2024.116452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2024.116452</ArticleId><ArticleId IdType="pubmed">39032318</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>